The Parkinson's disease (PD) market across the seven major markets (7MM*) is forecast to grow at a compound annual growth rate (CAGR) of 7.9%, from $3.3 billion ...

AMX-883, Amphista's first asset to enter the clinic, is a potent, selective, orally bioavailable DCAF16-mediated BRD9 degrader targeting acute myeloid leukaemia...

Bringing together scientific and technical expertise to advance development of hardware and software aimed at enabling a new wave of AI-driven, autonomous biolog...

·       Prof Dame Carol Robinson (University of Oxford), Dr Andrew Doré (Isomorphic Labs) and Prof Paula Booth (King’s College Lond...

Following a horizontal acquisition in December 2025, the companies are realising marked synergies under an ambitious integration program that has successfully al...

Scientists can now connect company-approved AI providers such as Claude Code and GitHub Copilot directly to Flare, helping teams set up, execute, and analyze com...

Phillips Medisize, a Molex company and a leader in the design, development, engineering and manufacturing of pharmaceutical drug delivery, in vitro diagnostic an...

Saint-Julien adds bioconjugation and development capabilities that complement HPAPI andpayload expertise in Rodano, while the Concord, Ohio site doubles producti...

Advancing a differentiated active immunotherapy approach targeting alpha-synuclein in Parkinson's disease; first human data confirm unique translational potentia...

Collaboration combines CellCarta's global clinical trial testing capabilities with Waters' standardised flow cytometry platforms and expertise CellCarta, ...